DK1425404T3 - Vaccinia-MVA-E3L-mutanter og anvendelse deraf - Google Patents
Vaccinia-MVA-E3L-mutanter og anvendelse derafInfo
- Publication number
- DK1425404T3 DK1425404T3 DK02772289T DK02772289T DK1425404T3 DK 1425404 T3 DK1425404 T3 DK 1425404T3 DK 02772289 T DK02772289 T DK 02772289T DK 02772289 T DK02772289 T DK 02772289T DK 1425404 T3 DK1425404 T3 DK 1425404T3
- Authority
- DK
- Denmark
- Prior art keywords
- mva
- viruses
- mutant
- present
- mutants
- Prior art date
Links
- 206010046865 Vaccinia virus infection Diseases 0.000 title 1
- 208000007089 vaccinia Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144664A DE10144664B4 (de) | 2001-09-11 | 2001-09-11 | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
| PCT/EP2002/010199 WO2003023040A2 (en) | 2001-09-11 | 2002-09-11 | Vaccinia virus mva-e3l-knockout-mutants and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1425404T3 true DK1425404T3 (da) | 2008-10-06 |
Family
ID=7698583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02772289T DK1425404T3 (da) | 2001-09-11 | 2002-09-11 | Vaccinia-MVA-E3L-mutanter og anvendelse deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7049145B2 (da) |
| EP (1) | EP1425404B1 (da) |
| JP (1) | JP4406561B2 (da) |
| AT (1) | ATE399210T1 (da) |
| AU (1) | AU2002337083A1 (da) |
| CA (1) | CA2459754C (da) |
| DE (2) | DE10144664B4 (da) |
| DK (1) | DK1425404T3 (da) |
| WO (1) | WO2003023040A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| JP4606838B2 (ja) * | 2004-10-20 | 2011-01-05 | 富士フイルム株式会社 | 電子内視鏡装置 |
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| EP2424999A1 (en) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modified immunization vectors |
| EP2479272A4 (en) | 2010-10-14 | 2013-11-20 | Ajinomoto Kk | PROCESS FOR THE PRODUCTION OF MONATIN |
| FR2969497B1 (fr) * | 2010-12-27 | 2013-06-28 | Ceva Sante Animale | Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants. |
| JP6569209B2 (ja) * | 2014-01-07 | 2019-09-04 | ソニー株式会社 | 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法 |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) * | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| WO2017205674A1 (en) * | 2016-05-25 | 2017-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6287570B1 (en) * | 1998-11-23 | 2001-09-11 | Patricia L. Foley | Vaccine against swine influenza virus |
| WO2000073487A1 (en) * | 1999-05-27 | 2000-12-07 | Arizona Board Of Regents | Novel viral vectors having enhanced effectiveness with dramatically reduced virulence |
| WO2007034871A1 (ja) | 2005-09-22 | 2007-03-29 | Tokyo Electron Limited | 選択的プラズマ処理方法 |
-
2001
- 2001-09-11 DE DE10144664A patent/DE10144664B4/de not_active Expired - Fee Related
-
2002
- 2002-09-11 AT AT02772289T patent/ATE399210T1/de active
- 2002-09-11 DE DE60227268T patent/DE60227268D1/de not_active Expired - Lifetime
- 2002-09-11 WO PCT/EP2002/010199 patent/WO2003023040A2/en not_active Ceased
- 2002-09-11 DK DK02772289T patent/DK1425404T3/da active
- 2002-09-11 AU AU2002337083A patent/AU2002337083A1/en not_active Abandoned
- 2002-09-11 EP EP02772289A patent/EP1425404B1/en not_active Expired - Lifetime
- 2002-09-11 JP JP2003527104A patent/JP4406561B2/ja not_active Expired - Fee Related
- 2002-09-11 CA CA2459754A patent/CA2459754C/en not_active Expired - Fee Related
- 2002-09-11 US US10/488,987 patent/US7049145B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE10144664A1 (de) | 2003-03-27 |
| DE60227268D1 (de) | 2008-08-07 |
| JP4406561B2 (ja) | 2010-01-27 |
| JP2005502360A (ja) | 2005-01-27 |
| CA2459754C (en) | 2011-05-10 |
| EP1425404B1 (en) | 2008-06-25 |
| WO2003023040A3 (en) | 2003-11-27 |
| AU2002337083A1 (en) | 2003-03-24 |
| EP1425404A2 (en) | 2004-06-09 |
| DE10144664B4 (de) | 2005-06-09 |
| ATE399210T1 (de) | 2008-07-15 |
| US20050028226A1 (en) | 2005-02-03 |
| CA2459754A1 (en) | 2003-03-20 |
| WO2003023040A2 (en) | 2003-03-20 |
| US7049145B2 (en) | 2006-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| NO20056074L (no) | Hoy titer rekombinante influensavira til vaksiner og genterapi | |
| HUP9802217A2 (hu) | Rekombináns MVA-vírus és alkalmazása | |
| CY1105232T1 (el) | Κυτταρικες σειρες συμπληρωματικοτητας | |
| SI1554301T1 (sl) | VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE | |
| DK1185615T3 (da) | Rekombinante influenzavirus til vacciner og genterapi | |
| ATE508635T1 (de) | Virusvektoren und ihre verwendung bei therapeutischen methoden | |
| UA85536C2 (en) | Viral antigens | |
| UA82998C2 (ru) | Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| KR100469936B1 (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
| UA90098C2 (en) | Promoter of vaccinia virus | |
| CY1106570T1 (el) | Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων | |
| IL164179A0 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| DE602004015418D1 (de) | Rekombinantes mva und verfahren zur erzeugung davon | |
| DE60040219D1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
| ATE453708T1 (de) | Impfstoff gegen west nile virus | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| DK1554383T3 (da) | Rekombinante MVA-stammer som potentieller vacciner mod P. falciparum-malaria | |
| PT1383796E (pt) | Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações | |
| WO2024259078A3 (en) | Anti-tick vaccines and methods of use thereof | |
| SE0002498D0 (sv) | Papillomavirus vaccine | |
| BR0318026A (pt) | Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos | |
| WO2002078621A3 (en) | Replication-competent recombinant virus and methods of use thereof |